CRIS Current Research Information System

LAMBERTI, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.149
NA - Nord America 3.939
EU - Europa 2.234
SA - Sud America 332
AF - Africa 272
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 2
Totale 13.940
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.830
VN - Vietnam 2.253
SG - Singapore 1.701
CN - Cina 1.671
IT - Italia 654
HK - Hong Kong 459
DE - Germania 290
BD - Bangladesh 250
KR - Corea 248
BR - Brasile 242
SE - Svezia 238
GB - Regno Unito 214
IN - India 201
NL - Olanda 146
FR - Francia 142
IE - Irlanda 102
RU - Federazione Russa 96
FI - Finlandia 93
CI - Costa d'Avorio 78
JP - Giappone 70
CH - Svizzera 68
TG - Togo 58
CA - Canada 55
ID - Indonesia 51
AR - Argentina 47
BG - Bulgaria 40
ZA - Sudafrica 36
JO - Giordania 34
MX - Messico 34
PH - Filippine 33
AT - Austria 31
TH - Thailandia 30
IQ - Iraq 29
SC - Seychelles 29
TR - Turchia 24
PK - Pakistan 21
NG - Nigeria 19
TW - Taiwan 19
BE - Belgio 17
MA - Marocco 14
PL - Polonia 14
CL - Cile 12
ES - Italia 12
UA - Ucraina 12
AU - Australia 11
EG - Egitto 9
EC - Ecuador 8
EE - Estonia 8
HR - Croazia 8
LT - Lituania 8
SA - Arabia Saudita 8
TN - Tunisia 8
VE - Venezuela 7
GR - Grecia 6
PY - Paraguay 6
AZ - Azerbaigian 5
HU - Ungheria 5
KE - Kenya 5
LB - Libano 5
MY - Malesia 5
NI - Nicaragua 5
NP - Nepal 5
AL - Albania 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
JM - Giamaica 4
PT - Portogallo 4
RO - Romania 4
SN - Senegal 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
IL - Israele 3
KG - Kirghizistan 3
KW - Kuwait 3
KZ - Kazakistan 3
LU - Lussemburgo 3
PE - Perù 3
GE - Georgia 2
GT - Guatemala 2
IR - Iran 2
MK - Macedonia 2
MN - Mongolia 2
OM - Oman 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BY - Bielorussia 1
CR - Costa Rica 1
GF - Guiana Francese 1
GM - Gambi 1
GY - Guiana 1
HN - Honduras 1
HT - Haiti 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
Totale 13.928
Salva come PNG Salva come JPEG
Città #
Singapore 1.174
Ho Chi Minh City 644
Ashburn 609
Hefei 521
Hanoi 500
Hong Kong 432
San Jose 430
Santa Clara 253
Seoul 232
Fairfield 190
Chandler 185
Beijing 182
Southend 141
Boardman 128
Bologna 122
Dublin 100
Los Angeles 90
New York 87
Council Bluffs 86
Houston 85
Seattle 80
Princeton 79
Abidjan 78
Woodbridge 78
Da Nang 74
Dong Ket 74
Helsinki 69
Lauterbourg 69
Wilmington 69
Buffalo 67
Haiphong 62
Bern 61
Lomé 58
Tokyo 57
Milan 56
São Paulo 51
Bengaluru 46
Biên Hòa 46
Cambridge 46
Shanghai 44
Dallas 43
Sofia 39
Frankfurt am Main 38
Quận Bình Thạnh 38
Redondo Beach 38
Amman 33
Turin 33
Guangzhou 31
Jakarta 31
Munich 30
Ninh Bình 29
Chicago 28
Hải Dương 28
Can Tho 27
Rome 26
Ann Arbor 24
Falkenstein 24
Ha Long 24
Thái Nguyên 24
Hyderabad 21
Nuremberg 21
San Francisco 21
Amsterdam 20
Berlin 20
Johannesburg 19
Vicenza 19
London 18
Orem 18
Redmond 18
Tongling 18
Abeokuta 17
Atlanta 17
Brooklyn 17
Bắc Ninh 17
Des Moines 17
Florence 17
Lappeenranta 17
Mexico City 17
Montreal 16
Nanjing 16
Oldenburg 16
Thái Bình 16
Jinan 15
Phoenix 15
Vienna 15
Westminster 15
Wuhan 15
Naples 14
Toronto 14
Yubileyny 14
Hangzhou 13
Zhengzhou 13
Chengdu 12
Rimini 12
Tianjin 12
Vũng Tàu 12
Điện Bàn 12
Baghdad 11
Breda 11
Brussels 11
Totale 8.692
Salva come PNG Salva come JPEG
Nome #
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 925
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option? 244
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale 235
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 229
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 207
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 203
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review 195
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 193
Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors 188
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 185
Appendiceal goblet cell carcinoma has marginal advantages from perioperative chemotherapy: a population-based study with an entropy balancing analysis 181
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 181
Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas 179
Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC 176
Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors 174
The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? 174
Treatment of advanced gastro‐entero‐pancreatic neuro‐ endocrine tumors: A systematic review and network meta‐analysis of phase iii randomized controlled trials 174
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12CMutant Non-Small Cell Lung Cancer 170
Real-Life Use of [68Ga]Ga-DOTANOC PET/CT in Confirmed and Suspected NETs from a Prospective 5-Year Electronic Archive at an ENETS Center of Excellence: More Than 2000 Scans in More Than 1500 Patients 169
[68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time? 169
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 164
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 164
An Update on Appendiceal Neuroendocrine Tumors 161
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event 161
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 157
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers with Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels 155
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 154
Classic versus innovative strategies for immuno-therapy in pancreatic cancer 153
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer 149
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 147
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report 146
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort 144
Metachronous solitary metastasis to the thyroid gland from squamous cell carcinoma of the lung: a case report and literature review 143
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease 141
Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor 139
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective 139
Landscape and future perspectives of immunotherapy in neuroendocrine neoplasia 137
Multimodal strategy in localized merkel cell carcinoma: Where are we and where are we heading? 136
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers 133
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study 130
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors 130
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) 129
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study 129
Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors 125
The role of clinical and molecular factors in low-grade gliomas: What is their impact on survival? 124
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 124
Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications 123
Therapeutic options in lung neuroendocrine tumors: between established concepts and new hopes 122
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 121
The functioning side of the pancreas: a review on insulinomas 121
Lymph node ratio predicts efficacy of postoperative radiation therapy in nonmetastatic Merkel cell carcinoma: A population-based analysis 120
Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma 119
Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study 119
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC 118
Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET) 117
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC 115
An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances 115
Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges 114
Radiomics in advanced gastroenteropancreatic neuroendocrine neoplasms: Identifying responders to somatostatin analogs 113
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 113
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients 112
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study 112
Gastric neuroendocrine neoplasms 110
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 109
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database 106
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives 106
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study 104
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 104
Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study From the French Group of Endocrine Tumors (GTE) 103
Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab? 100
Challenges and future perspectives for the use of temozolomide in the treatment of SCLC 99
Prophylactic cholecystectomy is not mandatory in patients candidate to the resection for small intestine neuroendocrine neoplasms: a propensity score-matched and cost-minimization analysis 98
β1600 Q.Clear Digital Reconstruction of [68Ga]Ga-DOTANOC PET/CT Improves Image Quality in NET Patients 96
Baseline neuronal antibodies in patients with small cell lung cancer are not necessarily associated with post-immune checkpoint inhibitors neurotoxicities 91
Reply to ‘The need for a better classification system for gastric neoplasms’ 87
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 86
The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis 86
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer 86
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 84
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer 83
Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study 83
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status 83
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 82
Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management 82
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 80
Non-small-cell lung cancer: how to manage RET-positive disease 78
Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis 77
BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: A case report and review of the literature 77
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3) 76
Cutaneous Scapular Lesion in an Elderly Woman 74
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities 74
ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS) 70
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 67
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 67
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1-2 cm 65
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 64
Should we lose hope in adjuvant therapy for neuroendocrine tumors?—In response to: Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit 64
Capecitabine and temozolomide or temozolomide alone in patients with atypical carcinoids 63
Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors 63
Molecular Imaging for Response Assessment of Neuroendocrine Tumors (NET). 62
Totale 13.328
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.123
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.123
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021163 0 0 0 0 0 0 0 0 0 0 0 163
2021/2022706 12 11 28 30 77 34 15 62 47 63 222 105
2022/20231.229 79 129 50 97 80 87 59 92 244 70 109 133
2023/2024490 36 60 34 40 37 110 24 67 14 32 20 16
2024/20252.682 114 250 264 192 360 139 212 104 37 179 231 600
2025/20268.235 1.602 890 594 556 590 315 692 377 1.241 525 504 349
Totale 14.319